Humacyte Announced Topline Results From V007 Phase 3 Trial Of Acellular Tissue Engineered Vessel (ATEV) In Arteriovenous Access For End-Stage Renal Disease Patients, ATEV Demonstrated Superior Function And Patency At 6 And 12 Months Vs. Autogenous Fistula
Portfolio Pulse from Benzinga Newsdesk
Humacyte announced positive topline results from its V007 Phase 3 trial of Acellular Tissue Engineered Vessel (ATEV) in arteriovenous access for end-stage renal disease patients. The ATEV demonstrated superior function and patency at 6 and 12 months compared to autogenous fistula.
July 31, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Humacyte's V007 Phase 3 trial results for ATEV in arteriovenous access for end-stage renal disease patients showed superior function and patency at 6 and 12 months compared to autogenous fistula.
The positive Phase 3 trial results indicate that Humacyte's ATEV is more effective than the current standard (autogenous fistula) for arteriovenous access in end-stage renal disease patients. This could lead to increased adoption of ATEV, boosting Humacyte's market position and potentially driving up the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100